ReviewJournal of the Academy of Consultation-Liaison Psychiatry
Dual Orexin Receptor Antagonists for Delirium: A Scoping Review and Feasibility Trial of Daridorexant.
Review in Journal of the Academy of Consultation-Liaison Psychiatry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNo medication is currently approved either for the prevention or treatment of delirium despite its tremendous clinical impact. Sleep-wake disturbances offer a promising target for delirium therapeutics, with a growing body of literature suggesting a potential role of dual orexin receptor antagonists (DORAs).
objectiveThis report provides a scoping review of the literature on DORAs for delirium and the results of a feasibility trial of daridorexant to prevent delirium after heart surgery.
methodsWe conducted a scoping review according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) for Scoping Reviews guidelines for peer-reviewed reports of DORAs for delirium. Next, we report sample characteristics and results for the feasibility aims from our single-site, double-blind, randomized placebo-controlled feasibility trial of daridorexant 50 mg given the first three nights after heart surgery to prevent delirium.
resultsOur scoping review includes 30 reports: 4 case reports/series, 1 clinical effectiveness project, 22 retrospective cohort studies, and 3 clinical trials. This literature is authored almost exclusively by teams from Japan. Most publications are on suvorexant. Although published data suggest a potential role for DORAs to prevent delirium, they remain inconclusive. We demonstrate the feasibility of our study (n = 11). In this preliminary trial, daridorexant-arm subjects had a numerically lower mean delirium symptom burden on postoperative days 1-3.
conclusionsThe evidence in support of DORAs for delirium calls for adequately powered efficacy trials. We also emphasize the importance of considering the pharmacokinetics of DORAs for delirium to maximize potential benefit and minimize the risk of next-morning sedation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.